{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:00:27Z","timestamp":1747177227571,"version":"3.40.5"},"reference-count":34,"publisher":"Informa UK Limited","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Cancer Investigation"],"DOI":"10.1080\/07357907.2023.2187225","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T15:12:10Z","timestamp":1677769930000},"page":"1-20","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms"],"prefix":"10.1080","author":[{"given":"Luis F.","family":"Gonzalez-Mosquera","sequence":"first","affiliation":[{"name":"Hematology and Medical Oncology Department, Henry Ford Hospital, Detroit, MI, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Moscoso","sequence":"additional","affiliation":[{"name":"ESPOL Polytechnic University, Escuela Superior Polit\u00e9cnica del Litoral, ESPOL, Centro de Investigaciones Economicas, Guayaquil, Ecuador."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pool","family":"Tobar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Cardenas-Maldonado","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nassau University Medical Center, East Meadow, NY, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alida I.","family":"Podrumar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nassau University Medical Center, East Meadow, NY, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3228-2244","authenticated-orcid":false,"given":"John A.","family":"Cuenca","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R,et\u00a0al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood2016 127(20):2391\u20132405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"CIT0002","doi-asserted-by":"crossref","unstructured":"Sankar K, Stein BL, Rampal RK. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.Cancer Treatment and Research2019 179:159\u2013178.","DOI":"10.1007\/978-3-030-20315-3_11"},{"key":"CIT0003","doi-asserted-by":"crossref","unstructured":"Rungjirajittranon T, Owattanapanich W, Ungprasert P,et\u00a0al.A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.BMC Cancer2019 19(1):184.","DOI":"10.1186\/s12885-019-5387-9"},{"key":"CIT0004","doi-asserted-by":"crossref","unstructured":"Yogarajah M, Tefferi A. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.Mayo Clinic Proceedings2017 92(7):1118\u20131128.","DOI":"10.1016\/j.mayocp.2017.05.010"},{"key":"CIT0005","doi-asserted-by":"crossref","unstructured":"Singer M, Deutschman CS, Seymour CW,et\u00a0al.The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA2016 315(8):801\u2013810.","DOI":"10.1001\/jama.2016.0287"},{"key":"CIT0006","doi-asserted-by":"crossref","unstructured":"Carvalho AS, Lagana D, Catford J,et\u00a0al.Bloodstream infections in neutropenic patients with haematological malignancies.Infection, Disease and Health2020 25(1):22\u201329.","DOI":"10.1016\/j.idh.2019.08.006"},{"key":"CIT0007","doi-asserted-by":"crossref","unstructured":"Brioli A, Klaus M, Sayer H,et\u00a0al.The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey.Annals of Hematology2019 98(3):713\u2013722.","DOI":"10.1007\/s00277-019-03621-1"},{"key":"CIT0008","doi-asserted-by":"crossref","unstructured":"Landtblom AR, Andersson TML, Dickman PW,et\u00a0al.Risk of infections in patients with myeloproliferative neoplasms\u2014a population-based cohort study of 8363 patients.Leukemia2021 35(2):476\u2013484.","DOI":"10.1038\/s41375-020-0909-7"},{"key":"CIT0009","doi-asserted-by":"crossref","unstructured":"Bauer M, Gerlach H, Vogelmann T,et\u00a0al.Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019\u2014 results from a systematic review and meta-analysis.Critical Care2020 24(1):239.","DOI":"10.1186\/s13054-020-02950-2"},{"key":"CIT0010","unstructured":"Nazer L, Lopez-Olivo MA, Cuenca JA,et\u00a0al.All-cause mortality in cancer patients treated for sepsis in intensive care units: a systematic review and meta-analysis.Supportive Care in Cancer 20222022 1:1\u201311."},{"key":"CIT0011","doi-asserted-by":"crossref","unstructured":"Manjappachar NK, Cuenca JA, Ram\u00edrez CM,et\u00a0al.Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria.Journal of the National Comprehensive Cancer Network2022 20(1):45\u201353.","DOI":"10.6004\/jnccn.2021.7046"},{"key":"CIT0012","unstructured":"HCUP-US NIS Overview. https:\/\/www.hcup-us.ahrq.gov\/nisoverview.jsp. July 6, 2021."},{"key":"CIT0013","doi-asserted-by":"crossref","unstructured":"Ulanja MB, Beutler BD, Antwi-Amoabeng D,et\u00a0al.Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample.Thrombosis Research2020 194:72\u201381.","DOI":"10.1016\/j.thromres.2020.06.017"},{"key":"CIT0014","doi-asserted-by":"crossref","unstructured":"Quan H, Sundararajan V, Halfon P,et\u00a0al.Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data.Medical Care2005 43(11):1130\u20131139.","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"CIT0015","doi-asserted-by":"crossref","unstructured":"Nazer LH, Lopez-Olivo MA, Brown AR,et\u00a0al.A Systematic Review and Meta-Analysis Evaluating Geographical Variation in Outcomes of Cancer Patients Treated in ICUs.Critical Care Explorations2022 4(9):e0757.","DOI":"10.1097\/CCE.0000000000000757"},{"key":"CIT0016","doi-asserted-by":"crossref","unstructured":"Cuenca JA, Manjappachar NK, Ram\u00edrez CM,et\u00a0al.Outcomes and Predictors of 28-Day Mortality in Patients With Solid Tumors and Septic Shock Defined by Third International Consensus Definitions for Sepsis and Septic Shock Criteria.Chest2022 (Online ahead of print).","DOI":"10.1016\/j.chest.2022.05.017"},{"key":"CIT0017","doi-asserted-by":"crossref","unstructured":"Wallace SK, Rathi NK, Waller DK,et\u00a0al.Two decades of ICU utilization and hospital outcomes in a comprehensive cancer center.Critical care medicine2016 44(5):926\u2013933.","DOI":"10.1097\/CCM.0000000000001568"},{"key":"CIT0018","doi-asserted-by":"crossref","unstructured":"Reyes MP, Cuenca JA, Heatter Juliana,et\u00a0al.Tribulations of conducting critically ill cancer patients research: Lessons from a failed septic shock trial and Murphy\u2019s law.Medicina Intensiva2022 46(10):582\u2013585.","DOI":"10.1016\/j.medin.2021.10.007"},{"key":"CIT0019","doi-asserted-by":"crossref","unstructured":"Coltro G, Mannelli F, Loscocco GG,et\u00a0al.Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.Blood Cancer J2022 12(8):116.","DOI":"10.1038\/s41408-022-00713-6"},{"key":"CIT0020","doi-asserted-by":"crossref","unstructured":"Guglielmelli P, Barosi G, Specchia G,et\u00a0al.Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.Blood2009 114(8):1477\u20131483.","DOI":"10.1182\/blood-2009-04-216044"},{"key":"CIT0021","doi-asserted-by":"crossref","unstructured":"Caocci G, Simula MP, Ghiani S,et\u00a0al.Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting.International Journal of Hematology2020 111(5):614\u2013618.","DOI":"10.1007\/s12185-020-02861-6"},{"key":"CIT0022","doi-asserted-by":"crossref","unstructured":"Sylvine P, Thomas S, Pirayeh E. Infections associated with ruxolitinib: study in the French Pharmacovigilance database.Annals of Hematology2018 97(5):913\u2013914.","DOI":"10.1007\/s00277-018-3242-8"},{"key":"CIT0023","doi-asserted-by":"crossref","unstructured":"Abidi MZ, Haque J, Varma P,et\u00a0al.Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.Case Reports in Hematology2016 2016:1\u20134.","DOI":"10.1155\/2016\/2389038"},{"key":"CIT0024","doi-asserted-by":"crossref","unstructured":"Chen C-C, Chen Y-Y, Huang C-E. Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib.Annals of Hematology2016 95(2):361\u2013362.","DOI":"10.1007\/s00277-015-2532-7"},{"key":"CIT0025","doi-asserted-by":"crossref","unstructured":"Lussana F, Cattaneo M, Rambaldi A,et\u00a0al.Ruxolitinib-associated infections: A systematic review and meta-analysis.American Journal of Hematology2018 93(3):339\u2013347.","DOI":"10.1002\/ajh.24976"},{"key":"CIT0026","doi-asserted-by":"crossref","unstructured":"Deininger M, Radich J, Burn TC,et\u00a0al.The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.Blood2015 126(13):1551\u20131554.","DOI":"10.1182\/blood-2015-03-635235"},{"key":"CIT0027","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Gotlib J,et\u00a0al.Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.J Hematol Oncol2017 10(1):55.","DOI":"10.1186\/s13045-017-0417-z"},{"key":"CIT0028","doi-asserted-by":"crossref","unstructured":"Hultcrantz M, Wilkes SR, Kristinsson SY,et\u00a0al.Risk and cause of death in patients diagnosed with Myeloproliferative Neoplasms in Sweden between 1973 and 2005: A population-based study.Journal of Clinical Oncology2015 33(20):2288\u20132295.","DOI":"10.1200\/JCO.2014.57.6652"},{"key":"CIT0029","doi-asserted-by":"crossref","unstructured":"Kreher S, Ochsenreither S, Trappe RU,et\u00a0al.Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncolo.Annals of Hematology2014 93(12):1953\u20131963.","DOI":"10.1007\/s00277-014-2224-8"},{"key":"CIT0030","doi-asserted-by":"crossref","unstructured":"Hultcrantz M, Wilkes SR, Kristinsson SY,et\u00a0al.Risk and cause of death in patients diagnosed with Myeloproliferative Neoplasms in Sweden between 1973 and 2005: A population-based study.Journal of Clinical Oncology2015 33(20):2288\u20132295.","DOI":"10.1200\/JCO.2014.57.6652"},{"key":"CIT0031","doi-asserted-by":"crossref","unstructured":"Williams MD, Braun LA, Cooper LM,et\u00a0al.Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care.Critical care (London, England)2004 8(5):R291-298.","DOI":"10.1186\/cc2893"},{"key":"CIT0032","doi-asserted-by":"crossref","unstructured":"Chindaprasirt J, Wanitpongpun C, Limpawattana P,et\u00a0al.Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia.Asian Pacific Journal of Cancer Prevention2013 14(2):1115\u20131119.","DOI":"10.7314\/APJCP.2013.14.2.1115"},{"key":"CIT0033","doi-asserted-by":"crossref","unstructured":"Moerer O, Schmid A, Hofmann M,et\u00a0al.Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use.Intensive Care Medicine2002 28(10):1440\u20131446.","DOI":"10.1007\/s00134-002-1429-9"},{"key":"CIT0034","doi-asserted-by":"crossref","unstructured":"Katiyar V, Uprety A, Mendez-Hernandez A,et\u00a0al.Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms.TH Open2019 03(03):e203\u2013e209.","DOI":"10.1055\/s-0039-1692988"}],"container-title":["Cancer Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/07357907.2023.2187225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:33:25Z","timestamp":1729010005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/07357907.2023.2187225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":34,"alternative-id":["10.1080\/07357907.2023.2187225"],"URL":"https:\/\/doi.org\/10.1080\/07357907.2023.2187225","relation":{},"ISSN":["0735-7907","1532-4192"],"issn-type":[{"type":"print","value":"0735-7907"},{"type":"electronic","value":"1532-4192"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icnv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icnv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}